Literature DB >> 19699244

Release characteristics and osteogenic activity of recombinant human bone morphogenetic protein-2 grafted to novel self-assembled poly(lactide-co-glycolide fumarate) nanoparticles.

Angel E Mercado1, Junyu Ma, Xuezhong He, Esmaiel Jabbari.   

Abstract

Functionalized biodegradable nanoparticles (NPs) provide reactive groups and large surface area for grafting recombinant human bone morphogenetic protein-2 (rhBMP-2) to reduce protein diffusion and maintain sufficient concentration for recruitment and differentiation of osteoprogenitor cells. The objective of this work was to investigate release characteristics and osteogenic activity of rhBMP-2, grafted to biodegradable NPs based on succinimide-terminated poly(lactide fumarate) (PLAF-NHS) and poly(lactide-co-glycolide fumarate) (PLGF-NHS) macromers. The release of rhBMP-2 from the NPs, measured by enzyme-linked immunosorbent assay, was linear with time in the first two weeks, and 24.70+/-1.30% and 48.7+/-0.7% of the protein grafted to PLGF-NHS and PLAF-NHS NPs, respectively, was released in the enzymatically active conformation after complete degradation/erosion of the NPs. After 14 days of incubation with bone marrow stromal (BMS) cells, rhBMP-2 grafted to PLAF-NHS and PLGF-NHS NPs was as effective in inducing mineralization as the native rhBMP-2 that was directly added to the cell culture media. At any incubation time, rhBMP-2 grafted to PLAF had the highest expression of osteopontin (OP) and osteocalcin (OC), followed by rhBMP-2 grafted to PLGF and rhBMP-2 directly added to media. Higher OP and OC expression for BMP-gPLAF and BMP-gPLGF groups may be related to other factors in the cascade of osteogenesis, such as differentiation of BMS cells to the vasculogenic lineage and formation of a vascularized/mineralized matrix.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699244      PMCID: PMC2783665          DOI: 10.1016/j.jconrel.2009.08.009

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  43 in total

1.  How porosity and size affect the drug release mechanisms from PLGA-based microparticles.

Authors:  D Klose; F Siepmann; K Elkharraz; S Krenzlin; J Siepmann
Journal:  Int J Pharm       Date:  2006-02-28       Impact factor: 5.875

Review 2.  Evidence supporting the use of bone morphogenetic proteins for spinal fusion surgery.

Authors:  Yohan Robinson; Christoph E Heyde; Sven K Tschöke; Michael A Mont; Thorsten M Seyler; Slif D Ulrich
Journal:  Expert Rev Med Devices       Date:  2008-01       Impact factor: 3.166

3.  Synthetic osteopontin-derived peptide SVVYGLR can induce neovascularization in artificial bone marrow scaffold biomaterials.

Authors:  Yoshinosuke Hamada; Hiroshi Egusa; Yoshitosi Kaneda; Isao Hirata; Naomasa Kawaguchi; Takafumi Hirao; Takuya Matsumoto; Makiko Yao; Kiyoshi Daito; Mayuka Suzuki; Hirofumi Yatani; Michiharu Daito; Masayuki Okazaki; Nariaki Matsuura
Journal:  Dent Mater J       Date:  2007-07       Impact factor: 2.102

4.  Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex.

Authors:  Yong-Il Chung; Kang-Min Ahn; Seung-Ho Jeon; Seung-Young Lee; Jong-Ho Lee; Giyoong Tae
Journal:  J Control Release       Date:  2007-06-02       Impact factor: 9.776

5.  The use of recombinant human bone morphogenetic protein 2 (rhBMP-2) to promote spinal fusion in a nonhuman primate anterior interbody fusion model.

Authors:  B P Hecht; J S Fischgrund; H N Herkowitz; L Penman; J M Toth; A Shirkhoda
Journal:  Spine (Phila Pa 1976)       Date:  1999-04-01       Impact factor: 3.468

6.  Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion.

Authors:  Lisa B E Shields; George H Raque; Steven D Glassman; Mitchell Campbell; Todd Vitaz; John Harpring; Christopher B Shields
Journal:  Spine (Phila Pa 1976)       Date:  2006-03-01       Impact factor: 3.468

7.  Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis.

Authors:  Daria Leali; Patrizia Dell'Era; Helena Stabile; Barbara Sennino; Ann F Chambers; Antonella Naldini; Silvano Sozzani; Beatrice Nico; Domenico Ribatti; Marco Presta
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

8.  Effect of grafting RGD and BMP-2 protein-derived peptides to a hydrogel substrate on osteogenic differentiation of marrow stromal cells.

Authors:  Xuezhong He; Junyu Ma; Esmaiel Jabbari
Journal:  Langmuir       Date:  2008-10-07       Impact factor: 3.882

9.  Cytotoxicity of Paclitaxel in biodegradable self-assembled core-shell poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles.

Authors:  Xuezhong He; Junyu Ma; Angel E Mercado; Weijie Xu; Esmaiel Jabbari
Journal:  Pharm Res       Date:  2008-01-15       Impact factor: 4.200

10.  Contact- and growth factor-dependent survival in a canine marrow-derived stromal cell line.

Authors:  R Huss; C A Hoy; H J Deeg
Journal:  Blood       Date:  1995-05-01       Impact factor: 22.113

View more
  10 in total

1.  Spatiotemporal release of BMP-2 and VEGF enhances osteogenic and vasculogenic differentiation of human mesenchymal stem cells and endothelial colony-forming cells co-encapsulated in a patterned hydrogel.

Authors:  Danial Barati; Seyed Ramin Pajoum Shariati; Seyedsina Moeinzadeh; Juan M Melero-Martin; Ali Khademhosseini; Esmaiel Jabbari
Journal:  J Control Release       Date:  2015-12-22       Impact factor: 9.776

Review 2.  Controlled release strategies for bone, cartilage, and osteochondral engineering--Part II: challenges on the evolution from single to multiple bioactive factor delivery.

Authors:  Vítor E Santo; Manuela E Gomes; João F Mano; Rui L Reis
Journal:  Tissue Eng Part B Rev       Date:  2013-01-30       Impact factor: 6.389

3.  Effect of grafting BMP2-derived peptide to nanoparticles on osteogenic and vasculogenic expression of stromal cells.

Authors:  Angel E Mercado; Xiaoming Yang; Xuezhong He; Esmaiel Jabbari
Journal:  J Tissue Eng Regen Med       Date:  2012-07-05       Impact factor: 3.963

4.  Spatiotemporal control of vascular endothelial growth factor expression using a heat-shock-activated, rapamycin-dependent gene switch.

Authors:  Francisco M Martín-Saavedra; Christopher G Wilson; Richard Voellmy; Nuria Vilaboa; Renny T Franceschi
Journal:  Hum Gene Ther Methods       Date:  2013-05-06       Impact factor: 2.396

5.  Experimental and computational investigation of the effect of hydrophobicity on aggregation and osteoinductive potential of BMP-2-derived peptide in a hydrogel matrix.

Authors:  Seyedsina Moeinzadeh; Danial Barati; Samaneh K Sarvestani; Tahereh Karimi; Esmaiel Jabbari
Journal:  Tissue Eng Part A       Date:  2014-10-01       Impact factor: 3.845

Review 6.  Nanotechnology in bone tissue engineering.

Authors:  Graham G Walmsley; Adrian McArdle; Ruth Tevlin; Arash Momeni; David Atashroo; Michael S Hu; Abdullah H Feroze; Victor W Wong; Peter H Lorenz; Michael T Longaker; Derrick C Wan
Journal:  Nanomedicine       Date:  2015-03-16       Impact factor: 5.307

Review 7.  Potential applications of engineered nanoparticles in medicine and biology: an update.

Authors:  Gudepalya Renukaiah Rudramurthy; Mallappa Kumara Swamy
Journal:  J Biol Inorg Chem       Date:  2018-08-10       Impact factor: 3.862

8.  Engineering of L-Plastin Peptide-Loaded Biodegradable Nanoparticles for Sustained Delivery and Suppression of Osteoclast Function In Vitro.

Authors:  Sunipa Majumdar; Aniket S Wadajkar; Hanan Aljohani; Mark A Reynolds; Anthony J Kim; Meenakshi Chellaiah
Journal:  Int J Cell Biol       Date:  2019-05-05

Review 9.  Nanoparticles and their potential for application in bone.

Authors:  Andrea Tautzenberger; Anna Kovtun; Anita Ignatius
Journal:  Int J Nanomedicine       Date:  2012-08-17

10.  Calcium ion-induced formation of β-sheet/-turn structure leading to alteration of osteogenic activity of bone morphogenetic protein-2.

Authors:  Wenjing Zhang; Hongyan He; Yu Tian; Qi Gan; Jing Zhang; Yuan Yuan; Changsheng Liu
Journal:  Sci Rep       Date:  2015-07-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.